https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 The involvement of TRPV1 in emesis and anti-emesis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22910 Suncus murinus revealed that it had "broad-spectrum" anti-emetic effects against stimuli acting via both central (vestibular system, area postrema) and peripheral (abdominal vagal afferents) inputs. One of several hypotheses discussed here is that the anti-emetic effect is due to acute depletion of substance P (or another peptide) at a critical site (e.g. nucleus tractus solitarius) in the central emetic pathway. Studies in Suncus murinus revealed a potential for a long lasting (one month) effect against the chemotherapeutic agent cisplatin. Subsequent studies using telemetry in the conscious ferret compared the anti-emetic, hypothermic and hypertensive effects of resiniferatoxin (pungent) and olvanil (non-pungent) and showed that the anti-emetic effect was present (but reduced) with olvanil which although inducing hypothermia it did not have the marked hypertensive effects of resiniferatoxin. The review concludes by discussing general insights into emetic pathways and their pharmacology revealed by these relatively overlooked studies with TRPV1 activators (pungent an non-pungent; high and low lipophilicity) and antagonists and the potential clinical utility of agents targeted at the TRPV1 system.]]> Wed 11 Apr 2018 13:53:25 AEST ]]> Metabolic profiling from an asymptomatic ferret model of SARS-CoV-2 infection https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46928 Thu 08 Dec 2022 12:25:53 AEDT ]]> Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45262 p=<0.0001) by up to a 24 fold (96% reduction) and in nasal wash (p=0.0107) up to a 15 fold (93% reduction) in comparison to untreated animals. Interpretation: The results of our study support clinical development of a therapy based on prophylactic TLR2/6 innate immune activation in the URT, to reduce SARS-CoV-2 transmission and provide protection against COVID-19.]]> Fri 28 Oct 2022 11:45:44 AEDT ]]>